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Amber N. Carrier 
May 11,2012 
Depression is one of the most frequent causes of disability worldwide. It can 
affect the psychological, social, and physical wellbeing of those that suffer from it, the 
majority of which are women. Depression has been linked to immune activation as well 
as serotonin depletion through a reduction in its precursor, tryptophan. Chlamydia 
trachomatis infection and estrogen can influence both the immune system and tryptophan 
levels, thereby biochemically inducing a depressive state. If this is the case, the use of 
exogenous estrogen through oral contraceptive pills (OCPs) could increase depressive 
symptoms, while the use of antibiotics to treat C. trachomatis infection could decrease 
depression. 
This thesis examined whether depression status in subjects was correlated with 
infection and medication use. Women were screened for depression at their annual 
gynecological exam, during which time they would receive an STI screen as standard of 
care. The study was conducted at the University of Louisville GYN/OB Foundation 
clinic and Campus Health Services from 2009-2011. Subjects were given a Beck 
Depression Inventory (BDI) to assess depressive symptoms and asked to keep a calendar 
vii 
of medication use. Subjects returned after one month to take a second BDI and their 
scores and medication calendars were compared with their medical records, specifically 
infection status and existing medical conditions. 
BDI scores decreased significantly in the follow-up assessment relative to the 
initial assessment. This decrease was correlated with the extent to which the subjects 
used mood-altering medications. Birth control use was correlated with an increase in 
depressive symptoms, but subjects who took mood-altering medication in addition to 
birth control were not more depressed than those that did not take birth control. There 
were insufficient data to correlate sexually transmitted infections, particularly C. 
trachomatis, with depressive symptoms. These findings show that increased hormonal 
birth control use is correlated with an increase in depression, but this depression is 
ameliorated with the use of mood-altering medication. These results imply that anti-
depressive medication may be particularly effective in treating depression associated with 
estrogen or oral contraceptive pills. 
viii 
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A Brief History of Evolutionary Medicine 
Theodosius Dobzhansky once said, "Nothing in biology makes sense except in the 
light of evolution." [1] Evolution is a framework upon which all of biology rests; the 
concept of change over time in heritable traits has reverberations in each branch of 
biology, from anatomy to ecology to genetics. The works of scientists such as Charles 
Darwin, lB.S. Haldane, Sewall Wright, and W. D. Hamilton have been accepted as 
fundamental to the modern understanding of the biological sciences. However, the field 
of medicine, which is founded on biological, chemical, and physical principles, has been 
slow to acknowledge how the core principles of evolution may influence the current and 
future practice of medicine. 
One exception to this generalization is the field of population genetics, which 
describes evolutionary change in terms of changing gene frequencies, and has been 
integrated into medical sciences for over a half century [2]. Explanations of the 
disappearance of the ability to digest lactose as an adult, the lack of alcohol 
dehydrogenase in certain groups of people, and the phylogeny of pathogens in order to 
predict future epidemics all have origins in evolutionary biology [3]. 
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Evolutionary medicine seeks to illustrate how and why the human body has innate 
vulnerabilities to disease, providing the clinician with new insight into how to respond to 
a set of symptoms because the clinician understands that the body works, as Nesse [3] 
puts it, as a "product of natural selection with traits more exquisite than any machine." 
Though this level of understanding seems as ifit would be intuitive to those who 
practice medicine, there has been some reluctance to directly apply evolutionary thinking 
to medical practice. This reluctance likely has its roots in our limited understanding of 
pathogens; we are still learning not only about the pathogenesis of infectious diseases but 
also how the body responds both acutely and chronically to these infections. Many of 
these pathogens, such as Varicella zoster in the case of shingles and Helicobacter pylori 
in the case of peptic ulcers and stomach cancer are cryptic in their presentation[4]. The 
pathology of other illnesses, such as multiple sclerosis and insulin-dependent diabetes 
mellitus, may be self-destructive immune responses to seemingly unrelated infections [5, 
6]. Of particular concern are pathogens in which transmission is infrequent; these 
infections are likely to benefit from long dormant periods and mechanisms for the 
evasion of host defenses. A prime example of these types of pathogens is sexually 
transmitted infections [4, 7]. 
STIs and Latent Infections 
Sexually transmitted infections are those that are commonly spread through 
vaginal, anal, or oral intercourse. These infectious may not be immediately symptomatic, 
and some, such as human immunodeficiency virus (HIV), can be present for many years 
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before the patient begins to display overt signs of infection [4, 7]. Other STI patients, 
such as those that suffer from Neisseria gonorrhoeae, which causes gonorrhea, often 
display overt symptoms much earlier, though overt symptomatology is not always the 
case. One of the reasons for continued infection and transmission of STIs is that many 
sufferers, particularly women, do not display overt symptoms of disease. Because of this 
crypticity of infection, sexually transmitted pathogens can initiate long-term infections 
with less risk of eradication through medical treatment. Their prolonged infectiousness 
facilitates transmission over periods of time that span changes in sex partners [4]. 
Sexually transmitted infections are very common both in the United States and 
worldwide. Women bear a heavier STI burden than men. According to the Centers for 
Disease Control, there were over 590 cases of Chlamydia trachomatis infection and 105 
cases of gonorrhea per 100,000 women in the United States, as opposed to 219 and 91 
cases per 100,000 men for Chlamydia trachomatis and gonorrhea, respectively [8]. In the 
case of Chlamydia trachomatis infection, the burden on women is nearly three times 
higher than it is for men, and over 1.2 million cases of Chlamydia trachomatis were 
reported to the CDC in 2009, but many more infections may remain unreported[8]. 
Chlamydial infections in women are usually asymptomatic and if left untreated, lead to 
pelvic inflammatory disease, the number one cause of infertility related to obstructed 
fallopian tubes [8, 9]. 
One of the reasons that Chlamydiae are able to establish long-term infections is 
that they are obligate intracellular pathogens. Such pathogens are difficult for the 
immune system to effectively eradicate because they reside within host immune cells; an 
immune mechanism to battle such infections includes starving the pathogen by depleting 
3 
essential nutrients such as vitamins, iron, and amino acids [10, 11]. Over the course of its 
evolutionary history, however, genitally acquired strains of C. trachoma tis have evolved 
the necessary genes to manufacture some of these nutrients, particularly tryptophan. 
Tryptophan is an essential amino acid that is restricted, or purposefully removed from 
circulation, by an enzyme called indoleamine 2,3-dioxygenase (IDO). The human body 
cannot manufacture tryptophan de novo and must obtain it from the diet, but C. 
trachomatis carries within its genome the genetic instructions for tryptophan synthase, an 
enzyme that manufactures tryptophan from other common molecules. In this way C. 
trachoma tis infections may persist as the body's own pool of available tryptophan 
dwindles. 
Tryptophan and Serotonin 
Depletion of the body's tryptophan stores is ultimately harmful for synthesis 
pathways that depend upon availability of the amino acid. One of these synthesis 
pathways is that for serotonin, a monoamine neurotransmitter found in the GI tract and 
the central nervous system (CNS) [12]. Within the CNS, serotonin aids in regulation of 
emotional behavior, and as a result is often referred to as a "happiness hormone" despite 
the fact that it is not a hormone [13, 14]. Serotonin is also part of the synthesis pathway 
of melatonin, an important mood stabilizer and sleep regulator [12]. The most commonly 
prescribed class of antidepressants, selective serotonin reuptake inhibitors (SSRIs), act to 
increase the availability of serotonin in the synaptic cleft, and therefore increase the 
amount of serotonin available to bind to the postsynaptic receptor, by preventing the 
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reuptake of the monoamine [15]. This increase in serotonin availability helps the patient 
to stabilize mood and has been shown to reduce depressive symptoms a great deal in 
those with clinically significant depression [16]. The efficacy of SSRIs in those with 
milder depressive symptoms is often disputed because the effect of SSRIs for those with 
mild depression is small [17]. 
Reductions in serotonin availability due to decreased tryptophan may contribute 
to depressive symptoms because overall serotonin availability and tryptophan levels have 
been correlated [18-20]. Research has indicated that acute tryptophan depletion can 
induce depressive symptoms in individuals that had previously experienced depression 
[21]. It is thought that tryptophan depletion by the immune system may be the reason 
that proinflammatory cytokines induce both depression and "sickness behavior," which is 
physiologically almost indistinguishable from depression [22-26]. Such a process might 
be occurring in patients infected with Chlamydia, whose immune systems may restrict 
tryptophan in order to combat a chronic infection that has evolved a mechanism for 
evading tryptophan starvation by manufacturing its own. 
Chlamydia trachoma tis and Depression 
If persistent Chlamydia trachomatis infection is depleting tryptophan stores, I 
hypothesize that women who are suffering from mild to moderate depression will have a 
higher frequency of undiagnosed Chlamydia trachomatis than women that show no 
depression (Chapter 2). If this is the case, upon diagnosis and treatment, not only should 
the infection be cleared, but also depressive symptoms should improve in the subject. 
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My thesis research attempted to test this idea. It was conducted at Campus Health 
Services, Belknap Campus and the University GYN/OB Foundation to examine if there is 
a correlation between undiagnosed Chlamydia trachomatis infection and depression, and 
if treatment of the infection ameliorates depressive symptoms in the subject (Chapters 3-
4). Discussion and limitations of the study are included in Chapter 5. 
Depression is a leading cause of disability [27, 28], and amelioration of some 
depression in the United States could save billions of dollars in health care costs and 
reduced productivity due to absenteeism [29]. There has been a great deal of research 
into the social circumstances and the biology of depression and its treatment, but little 
into the actual primary cause of depression[16, 30]. This dissertation seeks to explore a 
potential primary cause of this debilitating illness and provide an alternative treatment 
scenario for ameliorating depression that aims to eradicate the primary cause. 
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CHAPTER 2 
DEPRESSION AND THE IMMUNE SYSTEM 
Introduction 
Depression is a debilitating illness affecting 15-35 million Americans [31]. 
Though most people typically experience a depressing situation at some point in their 
lives [32] major depressive disorder is defined as a prolonged and unusually severe 
period in which normal function is disturbed [33]. Depression has been ranked as the 
number one cause of disability worldwide [27-29] and the costs incurred through 
treatment and productivity loss are in the billions. Major depressive disorder has a 
distinct emotional, social, and physiological effect on the sufferers in all aspects oflife 
[34]. Apart from the general malaise and the disability associated with low mood, 
depression takes a toll on the social and familial relationships in the sufferers' life. 
There is no singular cause of major depressive disorder (MDD); rather, a number 
of social and biological factors have been identified as contributing to the development of 
disease. Factors such as childhood poverty and a history of abuse and neglect are widely 
known to be linked to depression in adulthood[35]. Major life changes and stressors, 
including death of a loved one, divorce, and job 
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pressure are known social triggers for the disorder [36]. Other factors including 
neurochemical imbalances, alcohol and drug abuse, and neuroanatomical differences also 
increase the predisposition for developing depression. It is likely that the development of 
depression is multi-factorial, with influences from each category of disease causation: 
genetic, non-infectious environmental, and infectious [37](Figure 1). 
On the basis of high estimates of heritability and the physiological burden of the 
illness, some evolutionary psychologists believe that MDD may be an ancient behavioral 
adaptation that is somewhat maladaptive in modern environments [34]. Major depressive 
disorder usually begins during the first decade after reproductive maturity. Depression 
has been reported to result in late menarche, secondary amenorrhea, menstrual 
irregularity, and reduced live birth rate, decreasing overall female fertility [38] . 
Depression may persist evolutionarily because of compensatory benefits [34], such as 
socially appropriate behavior modification, improved social navigation, and avoidance of 
social risk [39-42]. Evolutionary psychologists also surmise that depression could be an 
adaptation that limits the transmission of causal infectious organisms[43] by encouraging 
the individual to rest and avoid others. Alternatively, it could be a side effect of the 
immune system's activation against the pathogen itself. 
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Figure 1. The triad of disease causation. Virtually every human illness is caused by 
at minimum genetic, infectious, or environmental, including social, factors ~ the 
majority of diseases are caused by a combination of the three. 
Infectiou 




nutrition, toxic chemicals, 
low water quality 
Depression and the Immune System 
There have been robust associations between chronic inflammation, stress, and 
depression. Major depressive disorder and other psychological disturbances are 
associated with increased host cell release of inflammatory markers and cytokines such as 
IFN-y, IL-6, chemokines, and acute-phase proteins [44-49] (see Table 1 below). These 
markers are modified proteins that serve as signaling molecules in the immune system. 
An increase in concentrations of IL-6 and C-reactive protein has been observed in plasma 
of depressed patients. Elevated concentrations of IL-1 (3, TNF -0, and IL-6 have been 
found in the peripheral blood and cerebrospinal fluid of depressed and/or suicidal patients 
[47,49-51]. Other chemokines and acute phase proteins elevated in patients with major 
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depression include a-I-acid glycoprotein, a-I-antichymotrypsin, haptoglobin[44, 52], 
human macrophage chemoattractant protein-I (MCP-I), soluble intracellular adhesion 
molecule-I (s-ICAM-I), and E-selectin. IL-2 production is reduced in depressed, 
dysthymic, and atypically depressed patients [50, 53, 54], but less so in the atypically 
depressed group that can still experience elevated mood in response to positive life 
events. These studies illustrate that there are differences in the presence of these 
immunological molecules in depressed vs. non-depressed patients, and that their 
concentrations may sometimes correlate with symptom severity [53, 54]. 
Table I. Immune molecules associated with depression. This non-exhaustive list includes molecules 
linked to both depression and sickness behavior. 





C-Reactive Protein Acute phase Binds to microbes and dead and dying cells to initiate 
protein complement binding during inflammation 
Interferon-a Type I Interferon Produced by leukocytes, involved in innate immune 
response against viruses 
Interferon-y Type II Interferon Promotes NK cells, Th 1 differentiation, leukocyte 
migration, antigen presentation on macrophages 
Interleukin-l p Cytokine Produced by macrophages to mediate inflammatory 
response 
Interleukin-2 Cytokine Produced by Thl cells; stimulates growth and 
differentiation of T -cells in response to antigen 
binding 
Interleukin-6 Cytokine Secreted by T -cells and macrophages to stimulate 
immune response, particularly to infection 
Tumor Necrosis Cytokine Induces apoptosis, inflammation; inhibits 
Factor-a tumorigenesis and viral replication 
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The question of exactly how cytokines may induce a depressive state remains in 
debate. Cytokines circulating in the bloodstream do not typically cross the blood brain 
barrier (BBB) but are transported into the brain via other means, such as 
circumventricular organs and carrier molecules [55]. Pro-inflammatory cytokines, 
particularly IL-l(3, TNF-a, IFN-y, and IL-6, partially mediate communication between 
the brain and the immune system through a saturable blood-to-brain transport system [55, 
56]. It is possible that cytokines and the immune system may influence depression by 
shunting valuable precursor molecules away from pathways necessary for 
neurotransmitter production. Tryptophan (Trp), an essential amino acid, is the precursor 
for the production of the neurotransmitter serotonin (5-hydroxytryptamine or 5-HT) and 
its hormonal derivative, melatonin (N-acetyl-5-methoxytryptamine), both of which are 
involved in mood regulation [18, 19, 57-62]. Serotonin is largely responsible for mood 
regulation within the brain. The most commonly prescribed class of anti-depressants, 
SSRIs, act to inhibit the reuptake of the chemical in the presynaptic cleft within the brain, 
thereby increasing the amount available for action [15]. The immunomodulatory enzyme 
indoleamine 2,3-dioxygenase (IDa) is up-regulated by IFN-y and other pro-inflammatory 
cytokines and functions to cleave tryptophan into kynurenine within extra-hepatic tissues 
[48,61-69]. When IDa cleaves the indole ring of tryptophan [64], it not only depletes 
the host and parasite of an essential amino acid, but also produces proapoptotic 
precursors of the kynurenine (kyn) pathway and toxic oxygen radicals [61, 62, 66, 68, 70, 
71]. Once this reaction takes place, there is less available tryptophan for serotonin 
production, and serotonin levels drop in the central nervous system, resulting in 
depressive symptoms [48]. Additionally, the intermediates of the kynurenine pathway, 
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collectively known as the kynurenines, have been shown in studies to be neurotoxic, 
although once transported away from the CNS they can be used to produce nicotinamide 
adenine dinucleotide (NAD), an important co-enzyme involved in energy metabolism 
[48] (Figure 2). 
During serotonin production, tryptophan is hydroxylated by the enzyme 
tryptophan hydroxylase (TPH) into 5-hydroxy-L-tryptophan, which is cleaved by an 
aromatic amino acid decarboxylase into serotonin (Figure 2). Since its oxygenation by 
TPH is the rate-limiting step in the serotonin synthesis pathway, levels of tryptophan and 
serotonin have been correlated in cerebrospinal fluid (CSF) [18-20, 72, 73]. 
Additionally, the use of radiopharmaceutical tryptophan and PET scans have confirmed 
the correlation between trp levels and serotonin synthesis in the brain [72]. 
Polymorphisms in the TPH gene have been linked with suicidal behavior [18,20] and 
variations in the levels of serotonin or its receptors and transporters have been associated 
with major depressive disorder. The addition of an acetyl group, followed by a methyl 
group, yields the neurohormone melatonin (Figure 2), produced by the pineal gland in the 
absence oflight [74]. Melatonin disruption leads to seasonal affective disorder (SAD) 
through a mechanism that may involve stimulation of type 1 T-Helper (Thl) cells and 
other lymphocytes to produce cytokines such as IL-2, IL-6, and IFN-y [74]. Exogenous 
tryptophan has been used as a treatment for both depression and sleep disorders, though 
the most common treatment for depression is currently the use of SSRIs [75]. 
When tryptophan is catabolized by IDO or tryptophan 2, 3-dioxygenase (TDO), a 
more specific enzyme that is known to exist only within the liver, the availability of the 
substrate for serotonin synthesis becomes limited. Depressive symptoms are found in 
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patients that have reduced serum tryptophan levels due to elevated IDO or TDO activity 
[19,58,60,62]. Since interferons are also potent mediators oflDO activity [61, 64, 69, 
74, 76, 77], elevated IDO activity and the subsequent drop in tryptophan levels due to 
inflammation could cause a decline in serotonin levels and a noticeable change in mood 
and demeanor. 
Proponents of this "cytokine hypothesis of depression" are split on whether 
cytokines are the cause of depression or are the mechanism by which another "insult" 
leads to depression. Smith first suggested in 1991 that depression was associated with an 
increase in secretion of IL-l by macrophages in his "macrophage theory of 
depression" [78]. Maes also believed that circulating monocytes and macrophages result 
in the increase of depression in patients [79]. Studies involving laboratory animals have 
shown that presence of inflammatory cytokines in the brain result in "sickness behaviors" 
that are indicative of depression, including anorexia, sleep disturbances, and the inability 
to feel pleasure. Inflammatory cytokines also have a stimulatory effect on the HP A axis, 
which modulates the stress response, depression, and immunity [44]. Cytokines disrupt 
proper serotonin, norepinephrine, and dopamine metabolism in neural centers that 
regulate emotional response. However, cytokines do not have the ability to cross the 
blood-brain barrier because of their size. Consequently, current research is focusing on 
exactly how these molecules can be found in the healthy brain. It is postulated that 
increased cytokine levels due to inflammation may degenerate the blood-brain barrier, 
thereby enabling cytokines and immune markers to enter the brain and influence mood 
[80]. 
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Cytokines such as IL-6 and IL-2 are associated with high Hamilton Depression 
Scale (HAM-D) scores in patients with chronic illnesses such as decompensated heart 
failure, hepatitis C, certain cancers and multiple sclerosis [47, 62, 81, 82]. A study by 
Appels et ai. in 2000 showed higher antibody titers in depressed and e~hausted patients 
who were receiving treatment for a coronary lesion [83]. These patients also showed 
elevated IL-1~, IL-6, and TNF -u. Evidence that exogenous administration of cytokines 
(particularly IFN-a, TNF-a, and IFN-y) results in an illness that is identical to major 
depression provides support to the argument that immune function, particularly 
inflammation, contributes to a depressive state [44,84,85]. This "sickness behavior" is 
often caused by up-regulation of IDO and tryptophan depletion, and it responds well to 
antidepressants [44, 86]. 
Medication administered to depressed patients has also been shown to have 
immunomodulatory effects. Antidepressants inhibit the production of proinflammatory 
cytokines and stimulate the release of anti-inflammatory cytokines; alternative 
antidepressant strategies such as electroshock therapy appear to attenuate the immune 
response, leading to decreased depressive symptoms [44]. Patients that have a history of 
impaired response to antidepressants typically display increased blood cytokine loads, 
particularly IL-6 [44, 52]. Anti-depressants treat immune-related depression but typically 
only address the mood-related symptoms rather than the outwardly physiologic 
symptoms such as lethargy, loss in appetite, and difficulty concentrating [78]. 
Additionally, cytokine antagonists such as IL-1 receptor antagonist appear to have anti-
depressive effects [22, 78]. 
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The impact of stress may also drive the development of immune-related 
depression in an otherwise healthy patient. Literature has suggested that psychological 
stress can stimulate the proinflammatory response [44]. Psychological stress is a causal 
factor in major depression and stressful events often precede depressive episodes. Both 
acute and chronic stresses are associated with increased production of proinflammatory 
cytokines and a decrease in circulating anti-inflammatory cytokines. 
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Figure 2. Tryptophan and the IDO pathway. The amino acid tryptophan is converted by tryptophan 
hydroxylase ultimately into serotonin, a neuroamine responsible for the maintenance of mood in the brain. 
However, if tryptophan is cleaved by IDO it results in the production of the neurotoxic kynurenine. 
Kynurenine is cleared by conversion into other necessary macromolecules, notably niacin and NAD. 
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Depression and Co-morbidity 
Depression is frequently co-morbid in illnesses in which immune dysfunction is 
apparent [78]. Many illnesses are known to involve or probably involve immune-related 
depression. Several of these diseases are considered below. I will first discuss immune-
related depression in Polycystic avary Syndrome patients. Then I will discuss 
depression in atherosclerosis patients. Finally I will discuss the comorbidity of 
depression with infection. 
Polycystic avary Syndrome 
Polycystic ovary syndrome (PCaS) is associated with alterations in mood. The 
characteristics associated with pcas, including abdominal obesity, acne, and hirsuteness, 
can lead to a depressed mood [87]. Unfortunately, few studies have assessed the co-
morbidity of PC as and mental illnesses such as major depressive disorder. Twenty to 
sixty-five percent of PC as patients are more depressed than controls [46, 80, 88-90]. 
Women with pcas were far more likely to present with other mental illnesses, 
particularly somatic illnesses such as anorexia nervosa and sleep disorders [80]. BMI, 
age, education, marital status, and employment did not explain the association of 
depression with pcas. 
Though obesity is a known risk factor for depression, PCaS-related obesity does 
not account for the co-occurrence of major depressive disorder [80, 91]. In fact, obese 
women with pcas have approximately six times the risk of developing major depressive 
disorder than obese women without pcas, suggesting that a PCaS-related factor may be 
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influencing the development of depression [80, 92]. abesity induces over-expression of 
such inflammatory markers as CRP and TNF-a, which is in turn associated with insulin 
resistance [46, 93]. Decreases in adiposity have been associated with decreases in freely 
circulating inflammatory markers [46, 99]. However, pcas patients, including those 
with normal BMIs, experience chronic low-grade inflammation with elevated C-reactive 
protein, TNF-a, IL-6, neutrophils and total leukocytes compared with age and BMI-
matched controls [94-99]. Another proinflammatory marker, macrophage migration 
inhibitory factor (MIF), is elevated in pcas patients independently of weight [100]. The 
genes for cytokines involved in the PCaS-related chronic inflammatory response, 
including TNF-a and IL-6, have been investigated in order to deduce the nature of the 
association between inflammation and pcas, but no PCaS-associated polymorphisms 
have as of yet been identified [98, 101]. 
Atherosclerosis 
Depression is associated with atherosclerosis and may occur prior to diagnosis. 
Depressed patients with no existing knowledge of cardiovascular health status display 
increased arterial stiffness [102, 103]. Patients with diabetes mellitus (DM) who score 
higher than lOon the Beck Depression Inventory are more likely to suffer from 
cardiovascular and dyslipidemic disorders [104]. This correlation is strong enough to 
suggest that physicians that notice depression in both DM and non-DM patients should 
consider a cardiovascular evaluation[104, 105]. Inflammation in the arterial wall is a 
key component of the cascade of atheroma formation. Leukocytes flood to the site of 
endothelial injury, and some of these, particularly macrophages, can sequester circulating 
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cholesterol and transform into foam cells within the lesion [106, 107]. Pro-inflammatory 
cytokines signal this inflammatory response, which can be detected both locally and 
systemically. In fact, circulating pro-inflammatory markers such as IL-6 and CRP can be 
used in a clinical setting to as a biomarker for atherosclerosis [106, 108]. Other immune 
markers correlated with depression are elevated in atherosclerotic patients; Elovainio et 
ai. found that depression was only associated with atherosclerosis in women with high 
IDO activity [109]. 
Acute and Chronic Infections 
A number of acute infectious illnesses such as influenza, gastroenteritis, and 
infectious mononucleosis (Epstein-Barr infection) are associated with both somatic and 
mood-related depression symptoms [55]. A combination of any or all offatigue, 
decreased psychomotor skills, anorexia, somnolence, lethargy, aches, cognitive 
disturbance, depressed mood, a sense of guilt, and difficulty in decision making have 
been reported in those suffering from influenza and other viral infections. Viral 
infections stimulate the production of type I interferons and activate NK cells; once 
infection has been established CD8+ Tc cells and CD4+ Th1 cells mount a more precise 
antiviral response [110]. This response includes the production ofIL-2, IFN-y, and tumor 
necrosis factor by Th1 cells. Some viruses, particularly those that exist as chronic 
infections, can either evade host defenses or cause immunosuppression. 
Extracellular bacterial pathogens incite an innate inflammatory response and 
cause to the release of inflammatory cytokines. However, innate immunity has little 
effect on intracellular bacteria, but these pathogens can induce a cell-mediated response 
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[110]. Cytokines secreted by CD4+ T cells, particularly IFN-y, direct macrophages to 
assist in killing ingested pathogens. Many common bacterial infections in the United 
States, including Campylobacter jejuni, the Salmonella group, Streptococcus 
pneumoniae, and Streptococcus pyogenes can induce symptoms similar to depression, 
particularly malaise, muscle weakness, and fatigue [110-114]. These symptoms are due 
to the immune response to these infections. The sickness behavior associated with these 
infections is nearly synonymous with depression and depressive symptoms [22]. Patients 
that are receiving interferon treatment for various infections often develop depression as a 
side effect within as little as one month from the initiation of treatment. 
Immune system-related depression is relatively common and sickness behavior is 
nearly identical to it. Because of this, it is logical to associate other illnesses in which an 
inflammatory response is generated with possible depression symptoms, particularly 
those with an infectious component. One bacterial infection that has not been examined 
in adequate detail with regard to its possible relationship to depression is Chlamydia 
trachomatis. 
Chlamydia and Depression 
Chlamydia trachomatis warrants particular scrutiny as a possible cause of 
depression due to some serovars' ability to produce tryptophan when IDO is elevated. 
Chlamydiae invade and live within host cells as obligate intracellular pathogens [64, 65, 
115]. They exist within humans in two forms: the infectious yet metabolically inert 
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elementary body (EB), and the non-infectious, intracellular but metabolically-active 
reticulate body (RB) [65]. Conversion between the two forms takes place within the host 
cell. Three biovars of C. trachomatis have been linked with human disease: ocular 
trachoma (caused by serovars A, B, Ba, and C), genital trachoma (serovars D-K), and the 
severe and systemically invading lymphogranuloma venereum (LGV) (serovars Ll, L2, 
and L3) [116]. There is very little cross-over between serovars and their infecting sites; 
the ocular serovars very rarely infect the genital tract, and the genital serovars generally 
only infect the eyes of infants when they pass through the birth canal [117]. The ocular 
and genital trachoma serovars are considered non-invasive, but the more rare LGV 
serovars proliferate within monocytes and lymphatic tissues and are highly invasive. The 
genital variants encode functional tryptophan synthase whereas the ocular variants do not 
[65, 116, 117]. A trpRBA operon codes for the tryptophan synthase alpha and beta 
subunits and the trp operon repressor. The deactivation of the repressor when tryptophan 
is scarce allows tryptophan synthase to produce tryptophan from indole, a readily 
available waste-product of many common vaginal flora [117]. This rescues Chlamydia 
from IFN-'1-induced tryptophan restriction in vitro. 
As obligate parasites of human cells, chlamydiae can largely evade detection by 
the humoral immune system. Some cytokines, though, are effective against C. 
trachomatis. IFN- '1 functions to clear C. trachomatis infection by up-regulating the 
production ofIDO. When IDO cleaves the indole ring of tryptophan [64], it not only 
depletes the host and parasite of an essential amino acid, but also the by-product, 
kynurenine, is toxic to Chlamydiae [61, 62, 66, 68, 70, 71]. Tryptophan depletion starves 
Chlamydiae but often leads to the formation of a persistent, aberrant state of infection 
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[61, 76, 118, 119]. Under this state, infections can become chronic, particularly the 
genital strains that are able to synthesize tryptophan de novo and evade the immune 
system's IDO response. 
Because of the ability of some persistent strains of C. trachomatis to synthesize 
tryptophan, a long-term infection is possible, even during immune activation and 
tryptophan restriction by IFN-y and IDO. However, long-term immune activation and 
elevated IFN-y levels may lead to other types of pathology such as the occurrence of 
depression due to a loss of serotonin. Because of the crypticity associated with C. 
trachomatis infections, particularly in the 70% of infected women that are asymptomatic, 
long-term C. trachomatis infection may lead to long-term symptoms of depression 
through biochemical means. 
Peri menstrual response to Infection and Depression 
Depressive symptoms in women are more frequent between puberty and 
menopause, and major depressive disorder (MDD) is twice as likely to occur in women 
as in men [66, 120-123]. Transitory depression is common and often occurs during major 
hormone fluctuation periods such as pregnancy, parturition, and menopause [120-122]. 
Estrogen fluctuation has been incriminated as a cause of this depression in part because 
of its effects on the IDO enzyme [123] and its temporal correlations with MDD [120]. 
Additionally, progesterone and its metabolites are correlated with peri menstrual 
symptoms such as fluid retention and emotional turmoil[124]. Both progesterone and 
estrogen dysregulate serotonin synthesis, and peri menstrual dysphoric disorder (PMDD) 
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and depression in women responds to treatment with SSRIs [125] and 
estrogen/progesterone containing low-dose birth control [123]. 
Estrogen and progesterone also modulate immune activity. Elevated progesterone 
during the luteal phase of the menstrual cycle is associated with a shift in immunity away 
from the Th1 response, leading to a decrease in the production ofIFN-y and other 
cytokines that are more effective in controlling intracellular bacteria[126]. Estrogen, 
which up-regulates IDO activity [126-128], is also elevated over the majority of the luteal 
phase. This appears to be a compensatory mechanism for the down-regulation ofThl 
activity during the luteal phase in order to provide some defense against intracellular 
bacteria by restricting tryptophan. This defense would be relatively ineffective against 
any genital serotypes of C. trachomatis because they can synthesize their own tryptophan 
[126]. Accordingly, transitory depression and C. trachomatis infection both covary 
within the menstrual cycle; both are exacerbated during the late luteal phase and the first 
few days of menstruation [124]. Depressive symptoms have been known to occur with 
sexually transmitted infections (STIs) [129] and C. trachoma tis in particular [28, 130]. 
In summary, depression is a debilitating illness with a distinct immunological 
component, and both hormones and infection might be key players in this interaction. 
The enzyme IDO functions to deplete tryptophan stores, and it is up-regulated by both 
estrogen and the immune system in response to intracellular infections such as C. 
trachomatis. Iftrp stores are depleted, there is less substrate with which to produce 
serotonin, and depression may result. 
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CHAPTER 3 
MATERIALS AND METHODS 
This clinical study (IRB 09.0226) of depression sought to detennine whether 
antibiotic treatment of Chlamydia trachomatis infection was associated with a subsequent 
amelioration of depressive symptoms. 
The goal was to enroll 100 patients from the University GYN/OB Foundation 
clinic that displayed evidence of depression during their annual gynecological check-up. 
This evidence included a physician's diagnosis of depression or the display of overt 
depressive symptoms. Subjects were pre-screened for eligibility by the physicians and 
medical assistants before their exams. Women between the ages of 18 and 40 who were 
non-menopausal (naturally or surgically), with relatively nonnal menstrual cycles and 
depressive symptomatology were invited to participate in the study. Each patient was 
compensated $10 at the initial visit, and $30 at a return visit one month later to assess 
depressive symptomology. 
A medical assistant asked eligible patients if they would like to participate in a 
volunteer questionnaire study on mood in gynecology patients. Each interested subject 
was directed to the researcher who gave her a flyer and explained the details of 
participation, the need to keep records on her medication use, and to return for a follow-
up visit one month after the initial visit 
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The patient was then given time to consider participation away from the 
researcher. If she agreed to participate she returned to the researcher to begin the consent 
process. 
The consent process consisted of the patient signing a Subject Informed Consent 
Document (SIC, Appendix A) and a HIP AA Research Authorization (HIP AA-RA, 
Appendix B) document. The researcher discussed each document with the subject, 
starting with the SIC so that the subject was aware of the scope and risks of the study 
before continuing. Each paragraph was explained orally and time was given for the 
subject to read it if she so chose. Once the subject had signed the informed consent 
document, the researcher discussed the HIPAA-RA with the subject in a similar manner 
and explained to the subject that in order to participate in the study the researcher would 
need access to some of the subject's medical records. The researcher then detailed the 
security procedures that protect the subject's Personal Health Information (PHI). 
Consenting subjects signed two copies of each document; one remained with the subject 
while the second remained with the researcher. After the subject's first visit, the 
researcher presented each SIC document to the three Principal Investigators of the study 
for signatures. The signed document's photocopy was mailed back to the subject. 
Once the SIC and the HIPAA-RA were completed, the subject was asked to 
complete Research Study Questionnaire (RSQ) to confirm her eligibility for the study and 
a Beck Depression Inventory II (BDI). The RSQ (Appendix C) consisted of six open-
ended questions intended to confirm the subject's age and health status, as well as to 
ensure accuracy when matching the patient's medical records to her BDI and calendar 
results. The RSQ also confirmed that the patients were pre-screened correctly. The BDI 
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(Appendix D), a widely respected standard in the psychological community for 
quantifying levels of depression, was used to quantify the degree of depression in the 
subject. Each question was read to the subject to reduce any effects of variation in 
literacy and language on the results of the questionnaire or BDl. 
The BDI assesses two measures of depression -- the psychological/cognitive 
symptoms and the physiologic (somatic or non-cognitive) symptoms [131]. The 
cognitive symptoms, including thoughts of suicide, pessimism, and past failure, are 
covered in questions 2,3, 5- 9, and 14. Somatic/non-cognitive symptoms, including loss 
of energy and agitation, are illustrated by questions 1,4, 10-13, and 15-21. Question 1, 
which addresses sadness, and question 10, which addresses crying behavior, have been 
associated with both cognitive and somatic symptoms, but are often classified as 
primarily somatic [131, 132]. 
After the patient completed these documents, the researcher scheduled each 
subject to return in approximately four weeks for her follow-up appointment. The 
researcher explained to each subject how to complete the calendar, document all 
medication use, and mark the day menstruation begins. The researcher requested that the 
subject note if there was a significant life event (described orally as a "car accident, 
family emergency, etc. ") that might influence the results during the study period. The 
researcher also explained that this information on life events could be helpful but was not 
required and that such an event would not exclude her from the study. The researcher 
then filled out the receipt (Appendix E), noting the subject's address and phone number, 
and gave the subject the first portion of her compensation. The subject was sent home 
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with a calendar (Appendix F) stapled to a purple file folder so that the calendar could be 
readily accessed. 
Deviations from the above protocol were made only in the event that the subject 
had a question about any aspect of the study. Such deviations were noted in the research 
database. 
A few days prior to each follow-up appointment (average 2.5 days), the subject 
was given a phone call to remind her of the study appointment and to confirm that the 
subject would be able to attend and return her calendar. If the subject needed to 
reschedule the appointment, this accommodation was made. At the follow-up 
appointment, the subject completed a second BDI and RSQ . She was compensated $30 
at this visit and filled out another receipt. See Figure 3 below for more information about 
the timeline of subject interaction. 

























for STI diagnosis 
The GYN/OB Foundation Clinic tests for C. trachomatis as part of the procedure 
associated with pap smears. It was expected that approximately 25% of the subjects 
recruited would test positive for C. trachomatis. If a patient tested positive for C. 
trachomatis or any other SII, the standard follow-up of the GYN/OB Foundation 
involved patient notification and mailing the standard antibiotic treatment to the patient. 
In the case of C. trachomatis, treatment was typically one dose azithromycin, 1 g by 
mouth. Some subjects, particularly those with penicillin allergies, were treated instead 
with rocephin (ceftriaxone) plus erythromycin base, amoxicillin, erythromycin 
ethyl succinate, or doxycycline (Table 2). Patients were instructed to record antibiotic 
usage on their calendars, as well as on the follow-up RSQ. These documents, when 
compared with the subject's medical records, allow identification of subjects who were 
Chlamydia-positive but did not complete the prescribed medication regimen. The RSQ 
and calendar also allowed detection of any other medication use that might influence the 
results of the BDI and sometimes provided indications ofa subject's immune status. The 
second BDI was intended to allow assessment of the antibiotic's effects on depressive 
symptoms. Each BDI was scanned upon completion to detect abnormally high scores 
that might indicate a need for immediate care from a mental health professional. If no 
such problem was found, the initial and final BDI were scored after the subject completed 
the study to maintain confidentiality and impartiality. 
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Table 2. Medications prescribed for treatment of Chlamydia infections. 
Azithromycin Azalide (macrolide) 19 by mouth 
Rocephin 
Cephalosporin 250 mg intramuscular injection 
(ceftriaxone) 
Erythromycin base Macrolide 500 mg by mouth for 1 day 
Amoxicillin ~-lactam 500 mg by mouth 3xJday for 7 days 
Erythromycin 800 mg by mouth 4xJday for 7 days or 
Macrolide 
ethylsuccinate 400 mg by mouth 4xJday for 14 days 
Doxycycline Tetracycline 100 mg by mouth 2xJday for 7 days 
After each subject completed her initial and final visit, both of her BDIs were 
scored and her medical records examined to determine her Chlamydia-positive status at 
the time of the initial visit. Any other diagnoses at this visit were also noted as well as 
any medications prescribed at the initial visit or later. When the researcher was taking 
notes only a three-digit study code identifier was used rather than the subject's actual 
name, and any notes on paper were shredded in a diamond shredder after they were 
entered into the subject database. 
All study data were entered into a password protected spreadsheet on an Apple 
Mac Book Pro running Mac OS X 10.7.2 (Lion). The spreadsheet was password-
protected for both changing and viewing the document. No subject identifiers (such as 
name, birth date, address, etc.) were entered onto the spreadsheet; the date of the BDI 
administration was therefore the only possible identifier entered. The subject's paper 
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documents, including her SIC, HIPAA-RA, RSQ, BDI, and receipts, were placed in the 
file folder with her calendar, marked with her three digit ID code on the tab, and stored in 
a locked filing cabinet in the Life Sciences Building at the University of Louisville. The 
only two individuals in possession of a key to this cabinet were Amber Carrier and Paul 
Ewald. All data from paper documents, excluding any subject identifiers, were entered 
into the subject database. Further analysis was conducted from this de-identified data set. 
Revised Protocol 
It was very difficult to obtain the number of subjects as originally planned. 
Explanations for this difficulty are discussed in Chapter 5. The following changes in 
protocol were made in a second phase of the study to facilitate recruitment. 
1. In November 2010, I spoke with Dr. Phillip Bressoud, Executive Director of 
Campus Health Services, and Dr. Kari Zahorik, Medical Director of Campus 
Health Services, about the possibility of working at Campus Health Services, 
Belknap Campus (215 Central Ave, Louisville, KY 40208) as a second subject 
recruitment site. The expected advantages of this site were higher availability of 
potential subjects, familiarity of potential subjects with simple research projects, 
and a high rate of STI transmission among college students. This addition 
required an amendment to the IRB protocol, approved January 27, 2011. I 
therefore began to recruit participants from this office in January 2011. 
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2. Campus Health Services does not automatically test for STIs unless the test is 
covered by the subject's health insurance, and one third of the student population 
does not have health coverage. An arrangement was negotiated with Louisville 
Metro Public Health and Well ness Department (LMPHW) to test for Chlamydia 
and Gonorrhea in uninsured subjects. I was provided with the test kits, and the 
staff at CHS utilized the LMPHW kits with uninsured subjects that agreed to 
participate in this study. I couriered the kits to LMPHW for testing and the results 
were faxed back to CHS. 
3. Purple post-it notes identifying subjects that might be eligible for the study were 
attached to the medical charts of women scheduled for an annual exam each day 
that I was present. This served to remind the medical assistants to pre-screen 
potential subjects. 
4. Several subjects at Campus Health Services had privacy concerns with mailing 
addresses and requested that I return their fully signed SIC at their next visit. I 
complied with these wishes, and gave future subjects this option without 
prompting. 
5. An advertisement for the study was placed in the SGA Student News. Once 
students responded via email, they were sent identical emails explaining the study 
and encouraging them to make an appointment at Campus Health. This was done 
to encourage potential subjects to make a gynecologic appointment at Campus 
Health, and served the greater public good by encouraging women to obtain their 
annual exam. A copy of the ad and the email can be found in Appendix G. 
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6. Because potential subjects were not often reporting depressive symptoms even 
though their BDI scores indicated low levels of depression, the decision was made 
to recruit all gynecological subjects into the study, not just those that were 
displaying overt depressive symptoms during their exam. 
7. Two research staff members, Laura Ovaitt (PhD student) and Samiyyah Sledge 
(undergraduate student) were added to the study, and recruited subjects under my 
supervision. Any subjects recruited by them are noted. 
Table 3. Timeline of events pertaining to the Study 
Date Event 
6/22/09 IRB Approval of project 
10/1109 Recruitment Begins in GYN/OB Foundation 
1127/11 CHS added as second recruitment site 
3/14111 Advertisement submitted to Student News 
9121111 Samiyyah Sledge added as study personnel 
10/5/11 Laura Ovaitt added as study personnel 
12/1111 Recruitment ends at OB/GYN 
12/1111 Recruitment ends at CHS 
1131112 Data Analysis 
Subjects might alter their tendency to report depressive symptoms to 
accommodate the researcher or because of a psychological effects of medical attention or 
participation in the study. In such situations, the BDI test scores could change even 
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when the underlying state of depression was not altered by antibiotic treatment. The 
questionnaire was administered to subjects who were not infected with C. trachomatis so 
that any reductions in depression associated with antibiotic treatment could be compared 
with changes among subjects who were untreated. If the results showed that antibiotic 
treatment of C. trachoma tis infection was associated with amelioration of depression, this 
association could serve as a basis for a follow-up case-control study. 
Statistical Analysis 
The presence of a non-parametric sample was confirmed via a Shapiro-Wilk test, 
a test appropriate for determining the normality of small sample sizes [133]. Normality 
plots were also constructed to graphically assess normality of the data. When 
distributions were non-normal, Wilcoxon signed rank test were used to determine 
whether amelioration of depression was associated with the second administration of the 
BDl. This test was chosen because the initial and final BDI scores are related and the 
differences can be considered ordinal. A Mann-Whitney U test was conducted when 
groups of paired scores were compared with each other. BDI sub-scores were assessed 
using cognitive vs. somatic symptoms to determine if the somatic symptoms that are 
similar to sickness behavior decreased when the subject took medication. Primary 
statistical analyses were conducted using SPSS version 20 [134], on a MacBook Pro 
running Mac OS X 10.7.2 (Lion). Power analyses were conducted using the freeware 





Twenty-four subjects completed the study. Nine additional subjects completed the 
first BDI but did not complete the study or were otherwise non-compliant (Table 4). The 
majority of subjects self-identified as Caucasian (16 total, two from GYN/OB and 14 
from CHS) but other categories included Hispanic (two from OB/GYN), Black (four 
total, two each from both sites), Asian (one from CHS) and of mixed race (one from 
CHS). 
Descriptive Statistics 
BDI scores and measures of variation in these scores for the two groups of study 
subjects are presented in Table 5. To assess whether the data met the requirements for 
parametric statistical testing, variances were compared and normality was evaluated. 
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Table 4, Subjects who did not complete the study or were otherwise non-compliant. 
', Su.,ject lD ~,~ ,";lii!ecruit"!;~:~f~ite ,;ae,~on for '~~t~!';\sion ,,~ 
,,"itt ;t,:(:;f~ 1~!~-' 11 :"~i' . ~,lif;p!f;%\'rW "'" ""I , ';'~;l*:" "',,' , ,,;, ,I • 
007 OB/GYN No Follow-up 
008 OB/GYN No Follow-up 
009 OB/GYN No Follow-up 
011 OB/GYN No Calendar 
013 CHS No Follow-up 
017 CHS No Follow-up 
019 CHS No Follow-up 
020 CHS No Follow-up 
033 CHS No Follow-up 
Table 5, Descriptive Statistics for subjects for whom BDI data is available, 
GYN/OB CBS Combined 
Mean Age 31 24 26 
Number of Subjects 8 17 25 
Mean Initial BDI 27.38 8.75 14.68 
Mean Final BDI 17.00 7.41 10.48 
Mean Difference -10.38 -l.34 -4.20 
Variance of Difference 152.26 37.97 88.42 
Std. Error Difference 4.36 l.50 l.88 
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The variances of the changes in BDI scores in the OBGYN (N=8) and CHS 
(N=17) populations were significantly different (Table 5, row 6, columns 1 and 2, 
F=8.286, p=0.009, Levene's test for unequal variances). The initial BDI scores deviated 
significantly from normality, as did difference in BDI scores (final score - initial score) 
(p=0.002 and 0.010 respectively, Shapiro-Wilk test, Figure 4). The final BDI scores did 
not (p=0.073, Figure 4). The threshold used for statistical significance was a=0.5. By 
this criterion, the changes in BDI scores in two subject pools were not significantly 
different from each other (N=25, p=0.086). The lack of statistical significance does not, 
however, provide a justification for combining the two populations because the nearness 
to statistical significance suggests that such a grouping would risk incorporation of a 
Type IT statistical error, particularly since power is low (13=0.59 for the difference). 
Considering this indication and the significant differences between the populations in 
normality and variance ofBDI scores (see above) tests were run separately on each group 
whenever sufficient data were available within each group. 
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Figure 4. Nonnality plots with initial BDI score (upper left), final BDI score (upper right), and difference 
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The BDI scores were significantly lower in the follow-up assessment relative to 
the initial assessment for the OB/GYN sample (p=0.035, Figure 5), but not in the CHS 
sample (p=0.36, Figure 6). A Fisher's combined probability test of both Wilcoxon-
Signed Rank scores indicated that overall the level of depression in the follow-up tests 
did not significantly decrease (p>0.30, X2 =3.812, df=4) . Subject 011 was included in 
this analysis because BDI data was available for her. 
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Figure 5. Wilcoxon Signed Rank of initial and final BDI scores of the OB/GYN sample. 
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Figure 6. Wilcoxon Signed Rank test of the initial and final BD! scores for the CHS sample. 
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Because of the similarity between sickness behavior and the non-cognitive 
symptoms of depression, the initial and final BDI scores were subdivided according to 
cognitive (affective) and non-cognitive (somatic) sub-scores (Table 6). The OB/GYN 
and CHS populations differed significantly within these categories for the initial and final 
scores (Table 6, row 1 versus row 4 and row 2 versus row 5; Table 7, rows 1 and 2. 
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Table 6. Affective and Somatic BDI scores for subjects. The affective BDI scores for all subjects ranged 
from 0-13 (out of a possible 24), and the rough somatic BDI scores ranged from 0-32 (out of a possible 39). 
0.67 7.60 5.12 0.96 15.61 
-0.53 0.44 3.27 -1.50 1.16 18.73 
9.43 1.29 11.62 19.00 3.30 76.33 
5.86 1.60 17.81 10.57 2.09 30.62 
-3.57 1.56 16.95 -8.43 3.20 71.62 
Table 7. Comparison ofBDI sub-scores in the CHS and OB/GYN populations. Entries are p values for the 
inter-site difference in the initial scores, the final scores and the change in the scores (final minus initial). 
Significant results are marked with an asterisk (Mann-Whitney U tests). Means for these categories are 
given in Table 6. 
0.016* 0.006* 
0.262 0.095 
The somatic sub scores were significantly lower on the final visit relative to the 
initial visit for the OB/GYN population but not for the CHS population (Table 8, row 2). 
A combined probabilities test indicated that overall the results were not significant 
(p>0.30, X2 = 3.79, df=4) . The affective sub scores were not significantly lower on the 
follow-up visit for either group (Table 8, row 1: p>0.30, X2 = 3.40, df=4, combined 
probabilities test). 
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Table 8. Comparison of change in BDI sub-scores in the final visit relative to the initial visit. Entries are p 
values for the differences between final and initial visits. Means for each category are given in Table 6. * 
denotes a statistically significant difference 
Affective 0.089 0.223 
Somatic 0.028* 0.452 
Only one subject tested positive for C. trachoma tis. I therefore could not assess 
whether pre-existing C. trachomatis infection was associated with higher BDI scores. 
Five subjects were infected with a sexually transmitted infection of some kind -- one each 
with trichomonas, chlamydia, and HPV; and two with bacterial vaginosis. Mean BDI 
scores for each group are presented in Table 9. The presence of a sexually transmitted 
infection was not significantly associated with initial, final, or overall change in BDI 
scores (p>O.l for all comparisons, Mann-Whitney U test). Subject 011 was included in 
this analysis because the BDI data was available for her. Because of the limited number 
of subjects that were STI-positive, only the pooled (CHS + OB/GYN) sample was 
analyzed. 
Table 9. Mean BDI scores of subjects based on infection status. There were no significant differences in 
scores between those that were infected with an STI vs. those who were not. 
Initial BDI 
Final BDI 8.80 10.90 
Difference -7.20 -3.45 
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Medication Analysis by class 
The large variety of medications used by the subjects (Table 10) and the small 
number of subjects prohibited statistical analysis on a medication-by-medication basis. 
Other than hormonal birth control, few medications were taken by more than one or two 
participants. Many of the medications, however, belonged to a smaller number of classes 
of drugs, which were prescribed for the similar reasons (Table 10). Medication 
categories were therefore used as variables in lieu of particular medications and all tests 
were run on all subjects from both study groups combined. 
Table lO. Medications used by patients. A detailed list of these medications is included in Appendix H. 
OTe Pain Relievers 
Mood Medications 
Antibiotics 
Other OTe Medications 
acetaminophen, aspirin, ibuprofen 
amitriptyline, bupropion, duloxetine, fluoxetine, 
lamotrigine, sertraline, trazadone, zolpidem 
amoxicillin, azithromycin, clindamycin, 
doxycycline, metronidazole 
azo yeast, melatonin, pepto bismol, prilosec, zantac 
Mood-altering medication is expected to ameliorate depressive symptoms. P-
values associated with mood-medication are therefore reported as one-tailed. The use of 
a mood-altering medication was significantly correlated with a decrease in BDI scores 
(one-tailed p=0.024, Table 11 row 2). 
None of the other classes of medications used were significantly associated with a 
change in BDI score, although the increase in BDI scores associated with hormonal birth 
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control was sufficiently close to statistical significance to suggest that honnonal birth 
control might actually be associated with less improvement in BDI score (p=0.078, Table 
11 row 4). 
Table 11. Tests for associations between change in BDI scores and medication use (Mann-Whitney U 
Tests). *denotes statistically significant difference 
Taken Not Taken 
'M~dication Class . ", n"~ ." Mean SD n Mean ~ .SD P 
OTC Pain Relief 16 -4.S6 6.72 8 -4.13 14.22 0.383 
Mood Medication 6 -9.83 8.86 18 -2.61 -9.29 0.024* 
Antibiotics S -8.40 14.84 19 -3 .37 7.86 0.891 
Birth Control 12 -l.33 8.1S 12 -7.S0 10.16 0.078 
OtherOTC S -2.60 3.S8 19 -4.89 10.60 0.891 
Birth Control Use 
Because associations with birth control bordered on statistical significance in 
several results, I analyzed the BDI results by grouping the subjects into those who used 
birth control versus who did not. 
Birth control pills used by all participants in the study were combination 
estrogen/progesterone oral contraceptive pills (OCPs) (Table 12). The specific 
progesterone varied based on the subject's prescription, but all subjects' oral 
contraceptives were fonnulated with ethinyl estradiol (BE), a bioactive derivative of 
estradiol (E2). The majority of subjects taking OCPs were exposed to 0.030-0.03Smg of 
EE with each pill. 
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Table 12. Subjects using oral contraceptive pills. Prescriptions varied with regard to dose and type of 
progestational compound. Subject 029's prescription contained a different formulation for each week of her 
cycle. 
lilSubj~ct {i\r ';'OCI» Bfand':' :". . FQrmbhition\l~j"ii ,. '(0~~114t*~i'" ':v'\"\~:ii'~!~i 
"'I.' :,~; . ;" 
003 low ogestrel 0.03 mg EE and 0.3 mg norgestrel 
014 levora 0.15mg 0.03 mg EE and 0.15 mg levonorgestrel 
015 gianvi 0.02 mg EE and 3 mg drospirenone 
016 ortho tri-cyclen 0.035 mg EE and 0.18 mg norgestimate 
021 sprintec 0.035 mg EE and 0.250 mg norgestimate 
022 ortho tri-cyclen 0.035 mg EE and 0.18 mg norgestimate 
024 levora 0.03 mg EE and 0.15 mg levonorgestrel 
025 ortho tri-cyclen 0.035 mg EE and O. 18 mg norgestimate 
026 sprintec 0.035 mg EE and 0.250 mg norgestimate 
027 levora 0.03 mg EE and 0.15 mg levonorgestrel 
029 tri -sprintec Week 1: 0.035 mg EE and 0.18 mg 
norgestimate; Week 2: 0.035 mg EE and 
0.215 mg norgestimate; Week 3: 0.035 
mg EE and 0.25 mg norgestimate 
030 unspecified 
Reports on the use of OCPs and their effects on depression vary; some studies 
have found that OCPs are correlated with a worsening of depressive symptoms in women 
with severe peri menstrual symptoms and/or a predisposition toward major depressive 
disorder [137, 138], while other studies have not confirmed this relationship. The use of 
OCPs for relief of severe peri menstrual syndrome (PMS) or perimenstrual dysphoric 
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disorder (PMDD) often treats only the pain and abnormal menstrual flow associated with 
these disorders and not the associated affective and somatic aspects of depression [139]. 
Since research indicates that estrogen influences the serotonergic pathway by up-
regulating tryptophan restriction [123], exogenous administration oflow-dose estrogen, 
such as that in an estrogen-containing OCP, may increase depressive symptoms in some 
women. 
This study indicated that there is a trend toward the use of OCPs and the 
worsening of depressive symptoms. Subjects who took OCPs and mood medication had 
significantly improved BDI scores relative to those who used OCPs but did not use mood 
medication (p=0.031 , Table 13, row 5). This improvement was significant for the 
affective sub scores (p=0.015, Table 13, row 3) but not in the somatic (p=0.089, Table 
13, row 4). However, subjects who did not take OCPs did not have improved BDI scores 
when using mood-related medication (p=0.467, Table 14, row 5). This difference 
indicates that subjects who used birth control may have initially been more depressed 
than those that did not use birth control (Table 11 , row 4), but the use of mood-altering 
medications ameliorated these depressive symptoms. 
Table 13. Tests for an association of BDI scores with mood-altering medication, among subjects who used 
birth control (Mann-Whitney U tests). * denotes a statistically significant difference 
Mood Meds No Mood Meds 
(n=2) (n=10) 
.'!i 
SD SD Mean "< Meant; , p to< , 
Initial BDI Score 21.00 14.14 8.30 9.90 0.091 
Final BDI Score 8.00 9.90 9.30 6.31 0.38 
Change in Affective Sub score -5.00 2.82 0.30 1.64 0.015* 
Change in Somatic Sub score -8.50 0.71 -0.75 4.33 0.089 
Change in Overall Score -13.00 4.24 1.00 6.50 0.031* 
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Table 14. Tests for an association of BDI scores with mood-altering medication, among subjects who did 
not use birth control (Mann-Whitney U tests). All p-values are one-tailed. 
Initial BDI Score 
Final BDI Score 
Change in Affective Sub score 
Change in Somatic Sub score 
Change in Overall Score 
Mood Meds 
n=4 






















DISCUSSION AND FUTURE CONSIDERATIONS 
Summary of Findings 
The original goal of the study was to detelTIline if changes in depressive 
symptoms were correlated with infection status, and if treatment of the infection led to an 
amelioration of depressive symptoms. I had hoped to study the association of depression 
with Chlamydia trachomatis but difficulties in subject recruitment led to a broadening of 
scope. 
The use of mood-altering medications such as fluoxetine (Prozac) and lamotrigine 
(Lamictal) was positively associated with the subject's change in BDI score. These 
medications are intended to alter mood symptoms and therefore this effect was not 
unexpected. Though these medications are classified in different drug classes (Appendix 
H), they are prescribed for the same effect -- to ameliorate depressive symptoms and 
mental illness in the patient. 
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The effect of birth control on increasing depressive symptoms approached 
significance in this study. The uncertainty associated with this finding reflects ambiguity 
about the roles of hormonal birth control in the literature. The effect of birth control, 
particularly OCPs, on depressive symptoms is controversial. The results of this study 
show, however, that depression in subjects taking hormonal birth control and mood-
altering medications declined over the course of the study. In contrast subjects who took 
mood medication but not hormonal birth control did not show such a decline. 
The exogenous estrogen introduced by OCPs may be up-regulating IDO, causing 
increased tryptophan restriction and therefore less serotonin synthesis. If this is the case, 
medications that are prescribed to reduce the re-uptake of serotonin, and therefore 
increase its availability in the synapse, may counteract the effects of estrogen in reducing 
serotonin synthesis. Though a number of subjects took mood-altering medications, only 
three used an SSRI, making it difficult to statistically show an association. 
The decline in BDI scores during follow-up could result from a "placebo effect" 
that arises from medical attention. Contact with a physician alone can be therapeutic, 
thereby improving the mood of subjects [140]. Since no physician contact occurred at 
the follow-up appointment, subjects that experience improved mood due to physician 
contact may have increased BDI scores, and therefore worse depression symptoms, 
without the physician's visit. Alternatively, anxiety about an upcoming doctor's visit and 
outright iatrophobia, or fear of doctors [141], are not uncommon phenomena and can 
result in some inflation of the initial BDI scores, since subjects were recruited at their 
annual exam. These subjects would have improved BDI scores at the follow-up since a 
doctor was not seen. 
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Limitations of the Study 
A variety of real and potential confounding factors limit the conclusions that can 
be drawn. As the study was clinical in nature and relied heavily on self-reported data, it 
was subject to the limitations of subjective clinical research. These issues, discussed in 
detail below, included recruitment, compliance, the self-report nature of the BDI, and the 
truthfulness of the subject. Additionally, protocol changes complicate interpretations. 
Recruitment 
The most critical limitation on the study was subject recruitment. Despite the 
offer of compensation for their time and travel, it was difficult to identify women who 
were willing to participate. Several factors may have negatively affected recruitment. 
One was subject referral. The physicians and the medical assistants were responsible for 
the initial mention of the study to potential subjects. This was accomplished either by 
mentioning the study directly or arranging for me to speak with the potential subject 
before her exam. Often no mention of the study was made during the potential subject's 
appointment, in which case the opportunity to recruit was lost. 
A second factor impeding subject recruitment was the subject's own hesitation to 
participate in the project. The most common reason, cited through personal 
communication with the subject at both CHS and the GYN/OB Foundation, was lack of 
time to stay for the initial visit. Subjects also mentioned that they were unable to return 
for the follow-up appointment. Since the initial visit took around 20-30 minutes total, 
subjects who had to return to work, go to class, or had other time constraints felt unable 
49 
to take the time both to consent to participate and fill out the Beck Depression Inventory. 
Several subjects approached at the GYN/OB Foundation did not directly decline 
participation but instead checked out and left immediately after the exam; staff speculated 
that these women held some distrust of the nature of the research due to not 
understanding the parameters. The medical assistants reported to me that these women 
seemed confused about the project and its scope despite my explanation to them. 
A substantially larger subject population would have allowed testing of the 
original hypothesis that antibiotic treatment of C. trachomatis led to an improved mood. 
The general tendency for mood scores to improve on follow-up visits, however, indicates 
that detection of an effect of antibiotic treatment would have been more difficult than 
originally anticipated; the improvement in mood among subjects treated with antibiotics 
would have to be greater than the more general improvement that was documented by 
this study. 
Compliance 
Failure to return for the follow-up visit was a major factor in subject non-
compliance. Eight subjects failed to return for their follow-up visits, despite repeated 
attempts to reschedule. An additional subject from the GYN/OB Foundation neglected to 
return her calendar but did complete a follow-up BDI. Without both the subject's final 
BDI scores and medication calendar, she was unable to be included in the final analysis. 
A number of subjects failed to note all of the information requested on their 
calendars. Most included the names of the medications that they were taking, but a few 
named a medication class rather than the exact medication itself. The most common 
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piece of information omitted, however, was the start date of menstruation. Only 16 of the 
24 subjects who completed the study included this information on their calendars. Only 
two subjects reported the use of depo provera, an injectable birth control that commonly 
alters menstruation frequency; these two subjects were also non-compliant subjects and 
were not included in the final analysis. It is unknown why these women did not complete 
this portion of the study. 
Self-report nature of the BDI 
As the BDI is a self-reported measure of depression, it is subject to the limitations 
of a subjective test [131, 142]. Although studies have indicated that it is a reliable tool in 
comparison to physician diagnosis [143], subjects may gauge their symptoms differently 
depending on any number of factors. The subjects may have exaggerated or minimized 
their symptoms based on the perceived desire of the researcher; for example, if the 
subject believed the researcher was hoping for a high score, she might be tempted to 
exaggerate her symptoms in an effort to please the researcher [142]. Subjects might be 
less likely to engage in such behaviors if the BDI was filled out in private or at home via 
postal mail, but these options would introduce other potential confounding factors. In an 
attempt to alleviate this risk, the researcher took precautions to not imply preferred results 
in either direction. 
The subject's current health status and daily mood changes may have also 
influenced the study. If the subject was having a "bad day" on the date of either her 
initial or final visit, she might be feeling more emotional, and therefore exaggerate the 
results of the test. In this case, the test would be a measurement "in the moment" rather 
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than over the long term. The converse is true for a perceived "good day." Additionally, 
the stress of the physician's office visit, any negative news administered by the physician, 
or any current or ongoing health problems may influence how the subject responds on the 
BDI. A recent short-term illness such as a cold or the flu may also alter the subject's 
short-term mood and therefore alter her BDI score. This should be partially 
accommodated for by the subject's report of her medication use on her calendar. 
Truthfulness 
The study is also limited by the subject's truthfulness and accuracy in reporting all 
medication use on her calendar. If the subject did not know the name ofa medication 
that was used, forgot to note a medication on her calendar, or labeled a medication 
incorrectly, the results of the study could be altered. Additionally, if a subject was using a 
medication incorrectly and was uncomfortable reporting this for fear of reprisal, her 
calendar results and potentially her BDI results would be inaccurate. It was stressed to 
the subjects to be as truthful, accurate, and honest as they could, and subjects were 
informed that the Health Insurance Portability and Accountability Act (HIP AA) required 
us to maintain confidentiality even in cases of illegal drug use. Each subject was 
reminded that the only situation where confidentiality would be breached is if the subject 
was an immediate danger to herself and/or others, and in this case we would only discuss 
it with her physician. However, some subjects may have omitted this information despite 
assurances of privacy. 
52 
Changes in Protocol 
There were changes made to the study protocol that may have had a minor effect 
on the results. Subjects at GYN/OB Clinic were read their surveys, while those at CHS 
were allowed to read them themselves. The decision was made to read the subjects at 
GYN/OB Clinic their questions due to possible comprehension issues since we could not 
be assured of the education level of the participants. However, it may have made 
subjects feel less at-ease with the study personnel. At CHS, all of the subjects were in 
college or graduate school, so reading comprehension was less of a concern. Though this 
could have potentially influenced the results, any influence would likely be minor. 
A Model for the Development of Depression 
Because of the multifactorial nature of the development of mental illness, it has 
historically been difficult to model the development of major depressive disorder. Many 
of the variables that influence depression development also have a single or bi-directional 
causal relationship on each other. For example, Kendler et al. developed two separate 
models for men [144] and women [145] based on 18 risk factors, 17 of which were 
shared and the single discordant factor (low parental warmth for men vs. disturbances at 
home for women) was part of the same childhood risk factor category. Both models had 
a relatively good fit despite their complexity, but neither model addressed how 
inflammation and sex hormones might influence the incidence of an episode of major 
depression. A simpler model developed by Wichers et al [146] teased out how genetic 
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influences that alter vulnerability to depression can have both a direct effect on 
depression development and an indirect effect by influencing negative life events, but this 
model also neglected to consider an immune system component of depression or the role 
of hormones. With the overall burden of depression higher for women, it is logical to 
consider how physiological differences between men and women may influence the 
development of depression. Because of the strong correlation of depression with sickness 
behavior, a well-balanced model for the development of depression should include an 
infectious/immune component as well. The development of a new model of depression 
that addresses hormonal milieu and the immune/infectious component is not within the 
scope of this study, but future work in this area may necessitate the construction of a new 
model that addresses these factors. 
Implications and Future Directions 
The results of this study suggest that anti-depressive medications may be 
particularly effective in ameliorating the depression associated with OCPs. This 
possibility needs to be explored in detail. It is possible that subjects who experience 
negative emotional side effects from birth control may benefit from use of an SSRI, or 
tryptophan supplementation in their diet, because OCPs may deplete tryptophan levels. 
Considering that many women who begin taking oral contraceptive pills discontinue 
them within the first year of use because ofPMS-like side effects [147], preemptively 
addressing the depression-like side effects could lead to a reduction in OCP 
discontinuation and ultimately fewer unplanned pregnancies. Since the use of hormonal 
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contraceptives is correlated with disease exacerbation, and estrogen up-regulates 
tryptophan restriction, it may be prudent to determine the depression and immune status 
of patients before hormonal contraception is prescribed, and to suggest non-hormonal or 
low-dose alternatives for patients who may be at risk for developing depression or other 
illnesses. 
These results from this study must be considered preliminary because of small 
sample size and uncontrolled variables. With a larger sample size and evaluation of 
correlates of medication use, the validity of the hypotheses raised by this study could be 
better evaluated. Blood draws to determine serum cytokine, IDO, and antibody levels 
may shed more light on the relationship between depression and the immune system. 
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louisville Department of Biology, Dr. Christine Cook MD, Uofl Department of Obstetrics and 
Gynecology and Dr. Rich lewine PhD, Uofl Department of Psychology. Approximately 100 local 
subjects will be invited to participate. Your partiCipation in this study will last for one (1) month. 
Purpose 
The purpose of this study is to examine changes in mood in relation to other medical factors such 
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Procedures 
This first part of the study is predicted to last approximately twenty (20) minutes. During this visit, 
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questionnaire will also be used to check and see if you are, in fact, eligible to take part in the study. 
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Once you have filled out both documents the second time, you will be compensated an additional 
$30 for your time and travel. 
Potential Risks 
There are no known physical risks linked with filling out these questionnaires or calendar. The only 
known risk associated with this study is the psychological stress of answering questions about your 
mood. In addition, you may suffer harms that we have not seen before. You may suffer harms 
that are worse than we have seen. 
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The possible benefits of this study include a more precisely directed treatment for your mood that 
may make your symptoms better. It is possible, however that the information may not benefrt you 
directly but, the information learned in this study may be helpful to others. 
Alternatives 
Instead of taking part in this study, you could choose to not participate and can drop out at any 
time. If you deCide not to participate in this study or stop participating at any time, you will not lose 
any benefits for which you may qualify. 
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As set forth in the Potential Risks section, there are no known risks or discomforts associated with 
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completing the questionnaires or calendar in this research study. Neither the study site nor the 
study doctors have set aside money to pay for treatment of any injury. You and your insurance will 
be billed for the treatment of these injuries. Before you agree to take part in this research study 
you should find out whether your insurance will cover an injury in this kind of research. You should 
talk to the study doctor or staff about this. If you are injured, there is no money set aside for lost 
wages, discomfort, disability, etc. You do not give up your legal rights by signing this form. If you 
think you have a research related injury, please call Dr. Paul Ewald at (502) 852-8816. 
Compensation 
You will be compensated for your time, inconvenience, or expenses while you are in this study. 
The total compensation is forty dollars ($40). You will receive ten dollars ($10) at enrollment with 
the completion of the first set of questionnaires. You will receive thirty dollars ($30) more at your 
second visit in four (4) weeks at the completion of the second set of questionnaires and turning in 
your calendar. 
Because you will be paid to be in this study the University of Louisville must collect your name, 
address, social security number, ask you to sign a W-9 form, and keep records of how much you 
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are paid more than $600 in one year by the University. We are required by the Intemal Revenue 
Service to collect this information and you may need to report the payment as income on your 
taxes. 
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private information. If you do not agree to give us this information, we can't pay you for being in 
this study. You can still be in the study even if you don't want to be paid. 
Costs 
If you are injured by the research, there may be additional cost for participating in the research. 
Otherwise there will be no additional cost to you. However, you or your insurance company will be 
billed for all office visits and procedures that are part of routine medical care. It is your 
responsibility to find out what costs, if any, your insurance company will cover before taking part in 
the study. 
HIPAA Research Authorization 
The Health Insurance Portability and Accountability Act of 1996 (HIPAA) provides federal 
safeguards for protected health information (PHI). Examples of PHI are your name, address, and 
birth date. PHI may also include your medical history, results of health exams and lab tests, drugs 
taken and results of this research study. Your PHI may not be used or shared without your 
agreement, unless it meets one of the HIPAA exceptions. If you agree to take part in this research 
you may be required to sign a "Research Authorization" form. This allows the use and sharing of 
your PHI by those listed in the "Research Authorization.· 
Confidentiality 
Total privacy cannot be guaranteed. We will protect your privacy to the extent permitted by law. If 
the results from this study are published, your name will not be made public. 
Consent version date ___ _ 
Page3of5 
76 
IRB 1109.0226: Exploratory Study on Mood Among Gynecology Patients 
The following may look at your research and medical records: 
• The sponsor and others hired by the sponsor to oversee the research 
• The University of Louisville Institutional Review Board, Human Subjects Protection Program 
Office, Privacy OffIce and others involved in research administration at the University 
• People who are responsible for research and HIPAA oversight at the institutions where the 
research is conducted 
• Govemment agencies, such as: (List all that apply) 
o Office for Human Research Protections, 
o OffIce of Civil Rights, 
• People responsible for billing, sending and receiving payments related to your participation 
in the study. 
Security 
Your data will be kept private by being stored on a password-protected computer that is only 
accessible to the investigators and study staff. Completed questionnaires will be stored in a locked 
file cabinet located in the Biology Department andlor the researcher's residence. 
Conflict of Interest 
There are no conflicts of interest regarding your participation in this study. 
Voluntary Participation 
Taking part in this study is completely voluntary. You may choose not to take part at all. If you 
decide not to be in this study, you won't be penalized or lose any benefits for which you qualify. If 
you decide to be in this study, you may change your mind and stop taking part at any time. If you 
decide to stop taking part, you won't be penalized or lose any benefits for which you qualify. 
You will be told about any new information leamed during the study that could affect your decision 
to continue in the study. 
Termination 
Your study doctor has the right to stop this study at any point. Your study doctor may take you out 
of this study with or without your okay. Reasons why this may occur include: determining that you 
do not suffer from shifts in mood or that you were not seen for a routine gynecological exam. 
Participation in Other Research Studies 
You may take part in this study if you are currently in another research study. It is important to let 
your doctor know if you are in another research study. 
Contact Persons 
If you have any questions, concems, or complaints about the research study, please contact Dr. 
Paul Ewald at (502) 852-8816 or Amber Carrier at (812) 454-4852. 
Research Subjecfs Rights 
Consent version date ___ _ 
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If you have any questions about your rights as a research subject, you may call the Human 
Subjects Protection Program Office at (502) 852-5188. You may discuss any questions about your 
rights as a research subject, in private, with a member of the Institutional Review Board (IRB). You 
may also call this number if you have other questions about the research, and you cannot reach 
the study doctor, or want to talk to someone else. The IRB is an independent committee made up 
of people from the University community, staff of the institutions, as well as people from the 
community not connected with these institutions. The IRB has reviewed this research study. 
Concerns and Complaints 
If you have concerns or complaints about the research or research staff and you do not wish to 
give your name, you may call the to/I free number 1-877-852-1167. This is a 24 hour hot line 
answered by people who do not work at the University of Louisville. 
Acknowledgment and Signatures 
This informed consent document is not a contract. This document tells you what will happen 
during the study if you choose to take part. Your signature indicates that this study has been 
explained to you, that your questions have been answered, and that you agree to take part in the 
study. You are not giving up any legal rights by signing this informed consent document You will 
be given a copy of this consent form to keep for your records. 
Do you want your primary care physician notified that you are a subject in this study? LlYes LlNo 
Printed Name of 
SubjectJLegal Representative 
Printed Name of Person 
Explaining Consent Form 
Printed Name of Investigator 
LIST OF INVESTIGATORS 
Paul Ewald, PhD 
Richard Lewine, PhD 
Christine Cook, MD 
Amber Carrier, PhC 
Consent version date, ___ _ 
Signature of Subject/Legal Representative Date Signed 
Signature of Person Explaining Date Signed 
Consent Form (if other than the Investigator) 
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AUTHORIZATION FOR USE AND DISCLOSURE OF YOUR 
HEALTH INFORMATION FOR RESEARCH 
IRB#: I Study Title I Exploratory study on mood among gynecology patients 
PRINCIPAL INVESTIGATOR/PROJECT DIRECTOR (PI/PO) 
Name (Last Name, First Name, MI) Email Address 
Ewald Paul' Cook Christine' Lewlne Richard Pw.ewald@louisville.edu 
Mailing Address - Include University Telephone Number 
Department (if applicable) (502) 852-8816 
L5218 Pager/Cell Phone Number 
Dept of Biology 
UofL Fax Number 
Lou., KY 40292 
Please read this form before you sign It. 
In our research, we will look at and may share information about you and your health. Federal 
law requires that health providers and researchers protect this Information and keep It private 
(confidential). "We" or "us" in this document refers to the following places (institutions, 
facilities, and practices) that are checked ("'). 
Affiliated Sites Non-Affiliated Sites 
[,(] University of Louisville (Do not remove this [] Louisville Metro Public Health & Wellness 
check.) 
[J Jewish HosQltal & St. Mary's Healthcare [] KY Cabinet for Health & Family Services 
[J Norton Healthcare, Inc., Including Kosalr [] Seven Counties Services 
Children's Hospital 
[J University of Louisville HospltaljJ. Graham [J other(s): 
Brown Cancer Center 
University of Louisville Research Foundation (ULRF) Clinical Sites 
[] Children & Youth Clinic 
[] Dentistry Clinics (Undergraduate DMD; 
Graduate, Perlo, Endo and Ortho; Oral Surgery 
and GPR at ACB; Faculty Practice, Graduate 
Pedodontic Clinic) 
[] Family Medicine - (Newburg and Central 
Station; also Geriatrics and Sports Medicine at 
Central Station) 
[J Harambee Nurslno Center 
[] Kidney Disease Program (Dialysis Unit and UL 
Renal Transp.ort Lab) 
[J Neonatal Follow Up Program 
Faculty Practice Group Sites 
[] University Anesthesiology AssoCiates, PSC 
[] University Radiological Assodates PSC 
[J University Physicians Associates (UPA)/ UPG -
Radiology, PSC 
[J University Emeroeney Medicine Associates PSC 
[] University Family Practice Associates PSC 
[] University Physicians AsSOCiates (UPA1 PSC 
[J University Medical Assodates (UMA), PSC 
[J Associates In Dermatology, PLLC 
[] University Neurologists PSC 
[] Neurosurgical Institute of Kentucky, PSC 
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UL Pathology Flow Cytometry Lab (BCC) 
UL Pathology Special Procedures Lab 
University Health Services (HSC and Belknap) 
Welsskopf Child Evaluation Center 
WHAS Crusade For Children Audiology & Speech 
Pathology Center 
WINGS Clinic - (ACB) 
University Pediatrics Foundation, Inc. d/b/a 
University Child Health Spedallsts, Inc.- (UCHS) 
University Children's Sleep Specialists LLC 
University Children's Infectious Disease 
Spedallsts LLC 
University Children's Kidney Specialists LLC 
Unlversl!y' Children's Sedation Service LLC 
University Pediatric Endocrinology, LLC 
Bone Marrow Transplant LLC 
Neonatal AsSOCiates PSC 
Pediatric & Perinatal Patholoov Associates PSC 
PediatriC Cardiology Assodates, PSC 
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[,(] Universitv GYN/OB Foundation Inc. [] Pediatric Hematolooy/Oncology Specialists PSC 
[] University OB/GYN Associates PSC [] Pediatric Pulmonary Medicine PSC 
[] Ophthalmological Services, Inc. - Primary Eye [] University Psychiatric Foundation, Inc. 
Clinic 
[] Eye Specialists of Louisville PSC [] University Psychiatric Services PSC 
[] Kentucky Vision Center Inc. [] University Radiotherapy Associates PSC 
[] Shea Tillett Malkani Caborn PSC [] University Surolcal Associates PSC 
[] Spine Institute PSC [] University Pediatric Surgery Associates PSC 
[] Orthopedic Trauma AssOCiates, PSC [] University Cardlothoracic Surgical AssOCiates, 
PSC 
[] University Patholooists PSC [] University Urolooy. PLLC 
[] Louisville Pathology Laboratory Associates Inc. [] Other: 
The law allows us to look at and share your health information for research, if you agree to let 
us do this and if we protect it as required. 
This form explains how we will look at and share your health information, as well as, who may 
see it and use your information. If you sign this form, it means you are letting us look at and 
share information for research. 
1. Health information about you from the items checked below may be looked at or 
given out to others. 
[] Consultation reports [ ] Records of your operation(s) 
[,(] Diaries and questionnaires [ ] Medical progress notes 
[ ] Discharge summaries [ ] Photos, videotapes, or digital or other 
images 
[ ] Healthcare provider orders [ ] Records about the study device 
[,(] History and physical exams [ ] Records about the study drug and other 
drugs you may be taking 
[,(] Laboratory, x-ray, and other tests [ ] Other: 
[] WE WILL NOT BE LOOKING AT ANY OF THE ITEMS LISTED BELOW FOR THIS STUDY. 
OR 
[,(] THE INFORMATION WE MAY LOOK AT OR GATHER FOR THIS RESEARCH MAY INCLUDE: 
[ ] HIV / AIDS status 
[ ] Hepatitis infection 
[,(] Sexually transmitted diseases 
[,(] The diagnosis and treatment of a mental health condition 
[,(] Other reportable infectiOUS diseases 
2. The following people or groups may share, receive and/or look at your information: 
The people and organizations listed on this form to conduct, analyze, and understand 
this study; 
You or your personal representative; 
Others as allowed or required by law; 
Government entities that have the responsibility to oversee this research; 
The offices and departments responsible for oversight of research at the University of 
Louisville; 
Health care providers and others where you receive care during your participation in 
this study; 
Health care providers and others, as appropriate, for compliance oversight; and 
People responsible for sending and receiving payments related to your participation in 
the study. 
Form: Research Authorization - FINAL (Rev 02-16-09) 
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In addition, the groups checked below may share, receive and/or look at your 
information: 
[ 1 The sponsor of the study and the people that the sponsor may contract with for the 
study. The name of the sponsor is: 
[ 1 Investigators and research staff at other places that are participating in the study; 
[1 An outside institutional review board (human subjects review board) 
[ 1 The Data Safety Monitoring Board 
[1 Other: 
If you have questions about who these people or organizations are, you may ask us. 
3. While we are required to protect your health information, once any information 
leaves our institutions, we cannot promise that others will keep it private 
(confidential). 
4. The information we look at or give to others as part of the research will be 
analyzed and further studied to answer the research questions and to make sure 
that the research was done correctly. 
S. You have the following rights: 
You do not have to sign this form. However, if you do not sign this form you will not be 
able to take part in this research. This will not change the health care or health care 
benefits you would otherwise receive. 
You may cancel the permission you have given in this form at any time. This means you 
can tell us to stop using and sharing your information. If you cancel your permission: 
We will stop collecting information about you. 
You may not withdraw information that we had before you told us to stop. 
o We may already have used it or shared it. 
o We may need it to complete the research. 
Staff may follow-up with you if there is a medical reason to do so. 
To cancel your permission, you should complete a written "Revocation of 
Research Authorization" form. Please send completed form to: 
Institutional Review Board 
MedCenter One, Suite 200 
501 E. Broadway 
Louisville, KY 40202 
A revocation form may be obtained from your study doctor, designated personnel or from 
the Human Subjects Protections Program Office website 
(http://louisville.edu/research/hymansubjects/subject-information). If you have any 
questions, call the Human Subjects Protections Program Office at (502) 852-5188. 
6. The time period when information can be used or shared ends when all activities 
related to this study are completed. 
7. Your access to your health information ["'] will [ ] will not be limited during this 
study. 
Form: Research Authorization - FINAL (Rev 02-16-09) 
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If you do not know what something means, you may ask us. Before you sign this, you may talk 
it over with someone you trust. You will be given a copy of this form after you have signed it. 
FOR ADULTS (OR MINORS) CAPABLE OF GIVING AUTHORIZATION: 
Subject's Signature Date Signed Printed Name 
FOR CHILDREN OR ADULTS NOT CAPABLE OF GIVING AUTHORIZATION: 
Signature of Parent/Surrogate/ 
Guardian/Health Care Agent for Subject 
Date Signed 
Relationship of representative (Surrogate) to Subject: 
NOTE: THE PRINCIPAL INVESTIGATOR MUST: 
Printed Name 
PROVIDE A COPY OF THE SIGNED AUTHORIZATION TO THE SUBJECT 
RETAIN THE ORIGINAL SIGNED AUTHORIZATION IN THE RESEARCH RECORD 
PLACE A COPY OF THE SIGNED AUTHORIZATION IN THE SUBJECT'S MEDICAL RECORD 
Form: Research Authorization - FINAL (Rev 02-16-09) 
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APPENDIXC 
Exploratory Study on Mood among Gynecological Patients 
18-40 Years-old 
• 
Name: ____________ date of birth: ____ _ 
Are you here for a routine exam? Yes/No 
What was the first day of your last menstrual period: _______ _ 
Did you have a pap smear and lab tests performed today? Yes / No 
Are you on any medications or have you taken any medicine in the last thirty 
(30) days (including vitamins, herbal supplements, topical ointments, 
suppositories)? Yes / No 
Ifyes,what ___________________ ___ 
Do you have any medical conditions? Yes / No 




Name: _____ ~. __________ Marital Status: ____ Age: ___ Sex: __ 
Occupation: ________________ Education: 
Instructiolls: This questionnaire consists of 21 groups of statements. Please read each group of Statements carefully, and 
then pick out the one statement in each group that best describes the way you have been feeling during the past two 
weeks, lDduding today. Circle the number beside the statement you have picked. If several statements in the group 
seem to apply equally well, circle the highest number for that group. Be sure that you do nut choose more than one 
statement for any group, including Item 16 (Changes in Sleeping Pattern) or Item 18 (Changes in Appetite). 
1. Sadness 
o r do nor feel sad. 
I feel sad tnIlCh of the time. 
2 r am sad all the time. 
3 I am so sad or unhappy that 1 can't stand it. 
2. Pessimism 
o 1 am not discouraged about my future. 
I feel more disoouraged about my future than 1 
nsed to be. . 
2 I do not expect things 10 work out for me. 
3 I feel my future is hopeless and will only get 
worse. 
3. Past Failure 
o r do not feel like a failure. 
I have failed more than I should bave. 
2 As 11001< back, I see a lot offailures. 
3 I feel I am a total failure as a person. 
4. Loss of Pleasure 
o I get as much pleasure as I ever did from Ibe 
lbings I enjoy. 
I I don't enjoy things as much as I used to. 
2 I get very little pleasure from lbe 1bings I used 
to enjoy. 
I can't get any pleasure from the things 1 used 
to enjoy. 
5. Guilty Feelings 
o I don't feel particularly guilty. 
I feel guilty over many things I have done or 
should have done. 
2 I feel quite guilty most of Ibe time. 
I feel guilty all of the time. 
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6. Punishment Feelings 
o I don't feel I am being punished. 
I I feel I may be punished. 
2 I expect to be punisbed' 
I feel I am being pnnished. 
7. Self-Dislike 
o I feel1he same about myself as ever. 
I I bave lost confidence in myself. 
2 I am disappointed in myself. 
I dislike myself. 
8, Sa if-Criticalness 
o I don't criticize or blame myself more than usual. 
I am more critical of myself than I used to be. 
I criticize myself for all of my faults. 
I blame my self for everything bad lbat happens. 
9. Suicidal Thoughts or Wishes 
o I don't bave any thougbts of!<illing myself. 
r have thoughts of killing myself. but I would 
not carry them out. 
I would like to !<ill myself. 
I would kill myself if I had the chance. 
10. Crying 
o I don't cry anymore Iban I used to. 
I cry more than I used to. 
I cry over every little lbing. 
I feel like cryiug, but I can't. 
__ Subtotal Page 1 
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r-------------------------------------,-------------------------------------, 1". Agitation ! 0 I am no more restless or wound up than usual. 
I I feel more restless or wound up than usual. 
2 I am so restless or agitated that ifs hard to stay 
still. 
I am so restless or agitated that I have to keep 
moving or doing something. 
12. loss Of Interest 
o I have not lost interest in other people or 
activities. 
I am less interested in other people or things 
than before. 
2 I have lost most of my interest in other people 
or things. 
3 It's hard to get interested in anything. 
13_ Indecislvaness 
o I make decisions about as well as ever. 
I find it more difficult to make decisions than 
usual. 
2 I have much greater difficulty in malting 
decisions than I used to. 
I have trouble making any decisions. 
14. Worthlessness 
o I do not feel I am worthless. 
1 I don't consider myself as worthwhile and useful 
as I used to. 
2 I feel more worthless as compared to other 
people. 
I feel utterly worthless. 
15. Loss 01 Energy 
o I have as much energy as ever. 
1 I have less energy than I used to have. 
2 I don't have enough energy to do very much. 
I don't have enough energy to do anything. 
16. Changes in Sleeping Panern 
o I have not experienced any change in my 
sleeping pattern. 
la I sleep somewhat more than usual. 
lb I sleep somewhat less than usual. 
2. I sleep a lot more than usual. 
2b I sleep a lot less than usual. 
3. I sleep most of the day. 
3b I wake up 1-2 hours early and can't get back 
to sleep. 
17. Irritability 
o I am no more irritable than usual. 
I I am more irritable than usUa!. 
2 I am much more irritable than usual. 
I am irritable all the time. 
18. Changes ill Appetite 
o I have not experienced any change in my 
appetite. 
1. My appetite is somewhat less than usual. 
Ib My appetite is somewhat greater than usual. 
20 My appetite is much less than before. 
~ .. ~l\{y appetite is much greater than usual. 
3. I have no appetite at alL 
3b I crave food all the time. 
19. Concentralion DiffiCulty 
o 1 can concentrate as well as ever. 
I I can't concentrate as well as usual. 
2 It's hard to keep my mind on anything for 
very long. 
I find I can't concentrate on anything. 
20. Tiredness or Fatigue 
o I am no more tired or fatigued than usual. 
I get more tired or fatigUed more easily than 
usual. 
I am too tired or fatigued to do a lot of the things 
I llsed to do. 
I am too tired or fatigued to do most of the 
things I used to do. 
21. loss of Interest in Sex 
o I have not noticed any recent change in my 
interest in sex. 
I am less interested in sex than I used to be. 
2 I am much less interested in sex now. 
3 I have lost interest in sex completely. 
___ Subtotal Page 2 










University of Louisville 
Human Subject Receipt for Compensation 




Amount of Compensation 
Date of Compensation ~~~~~~~~~~~~~~~~~~~~_ 
Signature ofParticipant~~~~~~~~~~~~~~~~~~_. 
(Please return this portion ofform to Controller's Office along with petty cash 
reconcilement or payment request.) 
Participant Code 
Amount of Compensation _~ __ ~_._~~~_~~~_~~~_~_ 
Date of Compensation __ ~~ ___ ~~ __ ~~ __ ~~ __ ~~~~_ 
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IRS NUMBER 09 .0226 
PLEASE WRITE DOWN WHAT MEDICINES YOU TAKE AND WHEN YOU TAKE THEM . 
ALSO, MARK WHEN YOU START YOUR PERIOD . PLEASE FILL THIS OUT EVERYDAY 
TO MAKE SURE IT IS CORRECT. PLEASE NOTE WHEN YOU ARE SCHEDULED TO RE-
TURN TO FILL OUT THE SECOND PAIR OF QUESTIONNAIRES AND RECEIVE THE 
REST OF YOUR COMPENSATION. 
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Female? Between 18 and 40? Is it time for a Check-up? 
If you're female and it's time for your annual check-up, you may be eligible to participate 
in a simple research study on mood. Eligible patients will fill out two short 
questionnaires on their mood and take home a calendar to track medication use. They 
will then be asked to return the calendar in a month and repeat the questionnaires. If you 
qualify, you will be compensated $10 at the first visit and $30 at the second for your time 
and participation. For more information about the study, please contact Amber N. Carrier 
at amber.carrier@louisville.edu 
STUDY EMAIL: 
Thank you for your inquiry about the study on mood in gynecology patients. 
To be eligible for the study, patients must be female, between the ages of 18 and 40, and 
present for an exam at Campus Health Services, Belknap Campus. You may be excluded 
from the study if you are not having certain tests done at your annual exam. 
Additionally, certain chronic diseases that affect the menstrual cycle may exclude you 
from the study (birth control is okay), but many other chronic conditions are okay. Your 
provider will determine your eligibility at your appointment. 
Our goal is to correlate health status, the menstrual cycle, and medication use with 
changes in mood over the course of the month. Eligible patients are recruited at the time 
of their annual exam. They are asked to fill out a couple of short questionnaires 
concerning their mood. They then take home a calendar on which they mark the days 
that they take certain medicines and when they start their period. Mter about a month, 
the patient is asked to return to fill out the questionnaires again. Each visit is brief 
(approximately 20 minutes at the first one, and 5-10 minutes at the second one). To 
compensate each patient for her time and participation, she will receive $10 at the first 
visit and $30 at the follow-up a month later, for a total of $40 for completing the study. 
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Please note that we do not cover the medical costs associated with your exam and any 
follow-up treatment. Please contact your healthcare insurer to determine if your health 
care coverage includes the cost of an annual exam. 
If you would like to schedule an appointment for your exam, please contact Campus 
Health Services, Belknap Campus at (502) 852-6479. At your exam, your provider will 
confirm if you are eligible to enroll in the study if you choose. The best times to 
schedule your appointment in order to ensure that I will be present and able to enroll you 
are on Monday, Wednesday, and Friday all day and Tuesday and Thursday afternoon. 
Other times I cannot guarantee that I will be available. Please contact me regarding 
Wednesday availability if that is when your exam is scheduled. If you cannot schedule 
an appointment at a time that I will be present, contact me and we can work out a time to 
enroll you in the study within a few days of your exam. 
If you have any further questions please feel free to contact me. I appreciate your 
interest! 
Sincerely, 
Amber N. Carrier 
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Tylenol, Lortab, Midol 
relieves pain from headaches, menstrual periods, muscle 










acetyl]amino}- 3,3-dimethyl- 7-oxo- 4-thia- 1-
azabicyclo[3.2.0]heptane- 2-carboxylic acid 
Amoxil, Trimox, Augmentin, Amoclan 
treats bacterial infections of respiratory tract, some STIs, 



































(2R,3S,4R,5R,8R, lOR, 11R, 12S, 13 S,14R)-2-ethyl-





treats bacterial infections of the lungs, reproductive tract, 
ears, skin, and throat 
macrolide antibiotic 
Bupropion 
(± )-2-(tert-Butylamino )-1-(3-chlorophenyl)propan-1-one 
Wellbutrin, Zyban 







treats bacterial infections of the lungs, skin, blood, 
internal organs, and female reproductive tract 
lincomycin antibiotic 
Diphenylhydramine 
2-( di pheny lmethoxy)-N,N -dimethy I ethanamine 
Benadryl, Sominex, Theratlu, Triaminic, PM variations 
of OTC pain relievers such as Advil and Tylenol 
relieves eye irritation, sneezing, runny nose, and allergy 
side effects. Also used to treat motion sicknes and 




















3,5,10,12, 12a-pentahydroxy- 6-methyl- 1,11-dioxo-
1,4,4a,5,5a,6,11,12a-octahydrotetracene- 2-carboxamide 
Vibramycin, Periostat 
treats bacterial infections of respiratory tract, skin, 







anti-depressant, GAD, pain due to diabetic neuropathy 
and fibromyalgia 
SNRI 
Ethinyl estradiol * 
19-Nor-17a-pregna-1,3,5(1O)-trien-20-yne-3,17-diol 
Present in almost all oral contraceptives, see below 
Prevents ovulation 
synthetic bioactive estradiol derivative 
*ethinylestradiol is the estrogen component of most combination oral contraceptive pills 















trifluoromethyl )phenoxy ]propan-1-amine 
Prozac, Sarafem 





Advil, Motrin, Midol 



































eliminates infections of reproductive tract, 
gastrointestinal tract, and skin 
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• National Conference on College Women Student Leaders, Washington, D.C., 
Summer 2008 
• National Conference on Graduate Student Leadership, Lexington KY, Fall 2007, 
Reporter 
• Kentucky Academy of Sciences Annual Meeting, Louisville, KY, Fall 2007 
Elected Positions 
• Graduate Student Council President (May 2008-May 2010) 
• Graduate Student Council Treasurer (May 2007-May 2008) 
• Biology Graduate Student Association Vice-President (May 2007-May2008) 
• Student Government Association Senator (December 2007-May 2010) 
Other Appointments 
• Class Act Federal Credit Union Supervisory Committee (Fall 20 1 O-May 2011) 
• Class Act Federal Credit Union Quality Control Committee (Fall 2009-Fall 2010, 
Chair) 
• Vice-President of Human Resources Search Committee (Summer 2009-Spring 2010) 
• Student Government Association Development Board (Summer 2009-May 2010, 
Chair) 
• Provost's Ad-hoc Budget Advisory Committee (Spring 2009-present; Chair, 
subcommittee on New Ideas; member; subcommittee on Closing Programs and 
efficiencies) 
• Graduate Council (Summer 2008-May 2010) 
• Student Government Association Executive Board (Summer 2008-May 2010) 
• University of Louisville Commission on the Status of Women (Winter 2008-Spring 
2011) 
• Biology Graduate Student Association Fundraising Committee (Fall 2006-Spring 
2008) 
• Graduate Student Council Events Committee (Spring 2007-Spring 2008) 
• University parking and Appeals Committee (Fall 2007-Spring 2008) 
• Student Organizations Board (Fall 2007-Spring 2008) 
• University of Louisville Strategic Planning Committee (Fall 2007) 
Courses Taught 
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• Human Anatomy and Physiology Laboratory, University of Louisville (Spring 2007, 
Spring 2009-Present) 
• Principles of Biology Laboratory, U ofL (Spring 2008) 
• Medical Microbiology Laboratory, U ofL (Summer and Fall 2007, Summer 2008, 
Summer 2009, Summer 2010) 
• Introduction to Biology for Non-Majors, U ofL (Fall 2006) 
PROFESSIONAL AND SCHOLASTIC SOCIETIES 
National Science Teachers Association, Golden Key International Honor Society, 
Omicron Delta Kappa Leadership Society, American Society of Microbiology, Sigma 
Zeta National Science and Mathematics Honor Society, American Association for the 
Advancement of Science, American Association of University Women, Association of 
Women in Science, Society for the Scientific Study of Sexuality 
HONORS 
• Office ofLGBT Services Amber Carrier Outstanding Student Ally Award (Spring 
2011; this was the inaugural year for the award and it was named in my honor) 
• Student Government Association Senator of the Year (Spring 2010) 
• Outstanding Graduate Student A ward (Spring 2009) 
• Christine Mirzayan Science and Technology Policy Graduate Fellow of the National 
Academies (2008) 
• University Delegate to the Biennial National Conference on Graduate Student 
Leadership (2007) 
• Biology Graduate Student Association Service Award (2007) 
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